Close Menu

A New Vector

Amit Nathwani at the University College London Cancer Institute and his colleagues tested a gene therapy approach for hemophilia B using an adenovirus-associated virus vector — one that's different from previously used adenovirus vectors — to deliver a corrected coagulation factor IX, or FIX, gene. As they report in the New England Journal of Medicine, Nathwani and his team performed a combined phase 1 and 2 clinical trial of their approach on six male patients with hemophilia B.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.